306 related articles for article (PubMed ID: 29856016)
1. Mouse Models of Huntington's Disease.
Farshim PP; Bates GP
Methods Mol Biol; 2018; 1780():97-120. PubMed ID: 29856016
[TBL] [Abstract][Full Text] [Related]
2. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
[TBL] [Abstract][Full Text] [Related]
4. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
Chang R; Liu X; Li S; Li XJ
Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
[TBL] [Abstract][Full Text] [Related]
5. Murine Models of Huntington's Disease for Evaluating Therapeutics.
Kosior N; Leavitt BR
Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
[TBL] [Abstract][Full Text] [Related]
6. Genetic Contributors to Intergenerational CAG Repeat Instability in Huntington's Disease Knock-In Mice.
Neto JL; Lee JM; Afridi A; Gillis T; Guide JR; Dempsey S; Lager B; Alonso I; Wheeler VC; Pinto RM
Genetics; 2017 Feb; 205(2):503-516. PubMed ID: 27913616
[TBL] [Abstract][Full Text] [Related]
7. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
9. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver B; Lee JM
Elife; 2024 Jun; 12():. PubMed ID: 38869243
[TBL] [Abstract][Full Text] [Related]
10. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
Flament J; Hantraye P; Valette J
Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
[TBL] [Abstract][Full Text] [Related]
12. Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.
André EA; Braatz EM; Liu JP; Zeitlin SO
J Huntingtons Dis; 2017; 6(1):47-62. PubMed ID: 28211815
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.
Ishiguro H; Yamada K; Sawada H; Nishii K; Ichino N; Sawada M; Kurosawa Y; Matsushita N; Kobayashi K; Goto J; Hashida H; Masuda N; Kanazawa I; Nagatsu T
J Neurosci Res; 2001 Aug; 65(4):289-97. PubMed ID: 11494364
[TBL] [Abstract][Full Text] [Related]
14. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.
Southwell AL; Smith-Dijak A; Kay C; Sepers M; Villanueva EB; Parsons MP; Xie Y; Anderson L; Felczak B; Waltl S; Ko S; Cheung D; Dal Cengio L; Slama R; Petoukhov E; Raymond LA; Hayden MR
Hum Mol Genet; 2016 Sep; 25(17):3654-3675. PubMed ID: 27378694
[TBL] [Abstract][Full Text] [Related]
15. HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction.
Kovalenko M; Milnerwood A; Giordano J; St Claire J; Guide JR; Stromberg M; Gillis T; Sapp E; DiFiglia M; MacDonald ME; Carroll JB; Lee JM; Tappan S; Raymond L; Wheeler VC
J Huntingtons Dis; 2018; 7(1):17-33. PubMed ID: 29480209
[TBL] [Abstract][Full Text] [Related]
16. Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG
Stefanko DP; Shah VD; Yamasaki WK; Petzinger GM; Jakowec MW
Neurobiol Dis; 2017 Sep; 105():15-32. PubMed ID: 28502806
[TBL] [Abstract][Full Text] [Related]
17. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.
Dietrich P; Johnson IM; Alli S; Dragatsis I
PLoS Genet; 2017 Jul; 13(7):e1006846. PubMed ID: 28715425
[TBL] [Abstract][Full Text] [Related]
18. Large animal models for Huntington's disease research.
Han B; Liang W; Li XJ; Li S; Yan S; Tu Z
Zool Res; 2024 Mar; 45(2):275-283. PubMed ID: 38485497
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
[TBL] [Abstract][Full Text] [Related]
20. Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.
Chen CM; Wu YR; Chang KH
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
